Enliven Therapeutics, Inc. (ELVN) Stock Analysis and Metrics

Enliven Therapeutics

NASDAQ: ELVN

$53.01 ▲ +0.20 (+0.38%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap3.35 Bn

P/E-28.57

Div. Yield0.00

Add ratio to table…

About

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The company applies a precision medicine approach that integrates validated biological targets with differentiated chemistry to design therapies that address unmet medical needs. Its lead program, ELVN-001, is a potent and highly selective ATP-competitive inhibitor targeting the BCR-ABL fusion protein for the treatment of chronic myeloid leukemia. In addition, Enliven Therapeutics is advancing ELVN-002, a central nervous system penetrant and irreversible HER2 inhibitor, and continues to explore research-stage opportunities in indications such as Graves’ disease. The company’s strategy emphasizes the selection of targets with strong biological validation and the creation of product candidates that combine efficacy with improved tolerability and convenient dosing.

As a pre-revenue entity, Enliven Therapeutics does not yet generate product sales from approved therapies. The company’s financial resources are derived primarily from equity financings, debt arrangements and potential grant or collaboration funding that support its research and development activities. Proceeds from these financing events are used to advance clinical trials, conduct preclinical studies, maintain intellectual property protection and cover general and administrative expenses. The company anticipates that future revenue could arise from product sales, licensing agreements, royalties or milestone payments should its pipeline candidates achieve regulatory approval and commercialization.

Within the oncology therapeutics market, Enliven Therapeutics competes against established tyrosine kinase inhibitors such as imatinib, dasatinib, nilotinib, bosutinib, ponatinib and the allosteric inhibitor asciminib. The company differentiates itself through the high selectivity of its small molecule candidates, which aims to minimize off‑target activity and reduce the incidence of adverse events that often lead to dose reductions or treatment discontinuation. This selectivity is intended to allow more flexible dosing regimens and potentially improve patient adherence compared with existing therapies that may require food restrictions or have significant drug-drug interactions. Enliven Therapeutics also emphasizes a target- and indication-agnostic approach that leverages its internal scaffold libraries and medicinal chemistry expertise to pursue a broad range of opportunities.

The company intends to serve patients diagnosed with chronic myeloid leukemia and other oncologic indications where its candidates demonstrate clinical activity. Healthcare providers who prescribe these therapies represent a key constituent of the intended customer base, as do the payers—including government health programs, managed care organizations and private insurers—that reimburse treatment costs. Enliven Therapeutics also anticipates engaging with specialty pharmacies and distribution channels that support the delivery of oral oncology medications. No specific customer names are disclosed in the filing.

Investment Thesis

▲ Bull case

ELVN's Phase 1b data for ELVN-001 demonstrates compelling efficacy in a heavily pretreated CML population, with a cumulative MMR rate of 69% by 24 weeks and 53% of patients achieving MMR by that timepoint, particularly notable given the 60/120 mg QD cohort (n=41) outperforming the 80 mg QD cohort, suggesting dose optimization potential; furthermore, 100% of patients who achieved MMR maintained it at the time of reporting, indicating durable responses that could translate to meaningful clinical benefit and differentiate ELVN-001 from existing TKIs where durability is often a concern, especially in later lines of therapy.
The company's strategic positioning around ELVN-001's mechanism as a highly selective active-site TKI with activity against the T315I mutation — the most common resistance-conferring BCR::ABL1 mutation — creates a unique value proposition, as this dual capability (targeting both wild-type and resistant clones) is not fully replicated by current standards like asciminib (allosteric) or ponatinib (pan-TKI with toxicity issues), potentially allowing ELVN-001 to capture significant share across all lines of therapy, including post-asciminib failure where preliminary data showed a 52% cumulative MMR rate in that subgroup.
With $452 million in cash, cash equivalents, and marketable securities as of Q1 2026, Enliven has a funded runway into the first half of 2029, which de-risks near-term execution and removes financing overhang as a concern, enabling the company to focus solely on advancing ELVN-001 through pivotal trials without dilution pressure; this financial strength is particularly critical given the capital-intensive nature of Phase 3 oncology trials and supports the guided initiation of ENABLE-2 in the second half of 2026.
The upcoming Phase 1 data update expected mid-2026 and the planned ENABLE-2 pivotal trial initiation in H2 2026 represent near-term catalysts that are underappreciated by the market, as successful completion of these milestones would validate ELVN-001's best-in-class potential and trigger re-rating ahead of any commercialization timeline, especially if the Phase 3 trial demonstrates non-inferiority or superiority to incumbent therapies with improved safety, particularly in the context of ELVN-001's favorable tolerability profile observed to date across 141 patients with a median treatment duration of ~32 weeks.
ELVN-001's complementary mechanism to allosteric inhibitors like asciminib opens a clear path for combination strategies, which management has hinted at as a future opportunity, and given the high unmet need in CML for deeper and more durable responses, especially in patients with complex resistance profiles, the ability to use ELVN-001 in backbone combinations could significantly expand its addressable market beyond monotherapy use, a long-term value driver not yet reflected in current valuations.

ELVN's Phase 1b data for ELVN-001 demonstrates compelling efficacy in a heavily pretreated CML population, with a cumulative MMR rate of 69% by 24 weeks and 53% of patients achieving MMR by that timepoint, particularly notable given the 60/120 mg QD cohort (n=41) outperforming the 80 mg QD cohort, suggesting dose optimization potential; furthermore, 100% of patients who achieved MMR maintained it at the time of reporting, indicating durable responses that could translate to meaningful clinical benefit and differentiate ELVN-001 from existing TKIs where durability is often a concern, especially in later lines of therapy.
The company's strategic positioning around ELVN-001's mechanism as a highly selective active-site TKI with activity against the T315I mutation — the most common resistance-conferring BCR::ABL1 mutation — creates a unique value proposition, as this dual capability (targeting both wild-type and resistant clones) is not fully replicated by current standards like asciminib (allosteric) or ponatinib (pan-TKI with toxicity issues), potentially allowing ELVN-001 to capture significant share across all lines of therapy, including post-asciminib failure where preliminary data showed a 52% cumulative MMR rate in that subgroup.
With $452 million in cash, cash equivalents, and marketable securities as of Q1 2026, Enliven has a funded runway into the first half of 2029, which de-risks near-term execution and removes financing overhang as a concern, enabling the company to focus solely on advancing ELVN-001 through pivotal trials without dilution pressure; this financial strength is particularly critical given the capital-intensive nature of Phase 3 oncology trials and supports the guided initiation of ENABLE-2 in the second half of 2026.
The upcoming Phase 1 data update expected mid-2026 and the planned ENABLE-2 pivotal trial initiation in H2 2026 represent near-term catalysts that are underappreciated by the market, as successful completion of these milestones would validate ELVN-001's best-in-class potential and trigger re-rating ahead of any commercialization timeline, especially if the Phase 3 trial demonstrates non-inferiority or superiority to incumbent therapies with improved safety, particularly in the context of ELVN-001's favorable tolerability profile observed to date across 141 patients with a median treatment duration of ~32 weeks.
ELVN-001's complementary mechanism to allosteric inhibitors like asciminib opens a clear path for combination strategies, which management has hinted at as a future opportunity, and given the high unmet need in CML for deeper and more durable responses, especially in patients with complex resistance profiles, the ability to use ELVN-001 in backbone combinations could significantly expand its addressable market beyond monotherapy use, a long-term value driver not yet reflected in current valuations.

▼ Bear case

Despite promising Phase 1 data, ELVN-001 lacks head-to-head comparative trials against established TKIs such as imatinib, dasatinib, nilotinib, or even asciminib and ponatinib, meaning the claimed "best-in-class" positioning remains speculative and dependent on indirect comparisons that may not hold in direct efficacy or safety evaluations, a risk heightened by the company's own disclaimer that cross-trial conclusions cannot be made due to differences in trial design, patient populations, and timing.
The CML market is increasingly saturated with effective therapies, including fourth-generation agents like asciminib which specifically target the T315I mutation with a favorable safety profile, reducing the incremental advantage of ELVN-001 even if it gains approval, as payers and physicians may be reluctant to adopt a new agent without clear superiority in outcomes, particularly given that current standards already achieve deep molecular responses in significant portions of patients, especially in earlier lines.
While the company cites a cash runway into H1 2029, this assumes no acceleration in R&D spending, yet initiating a global Phase 3 pivotal trial (ENABLE-2) in H2 2026 will likely significantly increase quarterly burn rates beyond the $27.8 million seen in Q1 2026, potentially shortening the effective runway if enrollment is slower than expected or if additional doses or arms are added, creating a hidden financial risk not fully apparent from the current balance sheet figure.
The reliance on MMR as a primary efficacy endpoint in early-phase data, while standard in CML trials, does not guarantee translation to meaningful clinical benefits like improved overall survival or transformation-free survival, and given that many patients in the ENABLE trial were heavily pretreated (including prior asciminib exposure), the durability of response beyond 24 weeks remains unproven at scale, with only small numbers maintaining MMR (n=3 and n=9 in the two cohorts) limiting confidence in long-term efficacy.
Enliven's limited experience as a company in designing and executing late-stage clinical trials introduces execution risk, particularly as it transitions from Phase 1 to pivotal Phase 3 development; the absence of prior regulatory approvals or commercialization experience among leadership increases the probability of missteps in trial design, endpoint selection, or interactions with the FDA, which could delay or derail the ENABLE-2 initiation timeline despite current guidance for H2 2026.

Despite promising Phase 1 data, ELVN-001 lacks head-to-head comparative trials against established TKIs such as imatinib, dasatinib, nilotinib, or even asciminib and ponatinib, meaning the claimed "best-in-class" positioning remains speculative and dependent on indirect comparisons that may not hold in direct efficacy or safety evaluations, a risk heightened by the company's own disclaimer that cross-trial conclusions cannot be made due to differences in trial design, patient populations, and timing.
The CML market is increasingly saturated with effective therapies, including fourth-generation agents like asciminib which specifically target the T315I mutation with a favorable safety profile, reducing the incremental advantage of ELVN-001 even if it gains approval, as payers and physicians may be reluctant to adopt a new agent without clear superiority in outcomes, particularly given that current standards already achieve deep molecular responses in significant portions of patients, especially in earlier lines.
While the company cites a cash runway into H1 2029, this assumes no acceleration in R&D spending, yet initiating a global Phase 3 pivotal trial (ENABLE-2) in H2 2026 will likely significantly increase quarterly burn rates beyond the $27.8 million seen in Q1 2026, potentially shortening the effective runway if enrollment is slower than expected or if additional doses or arms are added, creating a hidden financial risk not fully apparent from the current balance sheet figure.
The reliance on MMR as a primary efficacy endpoint in early-phase data, while standard in CML trials, does not guarantee translation to meaningful clinical benefits like improved overall survival or transformation-free survival, and given that many patients in the ENABLE trial were heavily pretreated (including prior asciminib exposure), the durability of response beyond 24 weeks remains unproven at scale, with only small numbers maintaining MMR (n=3 and n=9 in the two cohorts) limiting confidence in long-term efficacy.
Enliven's limited experience as a company in designing and executing late-stage clinical trials introduces execution risk, particularly as it transitions from Phase 1 to pivotal Phase 3 development; the absence of prior regulatory approvals or commercialization experience among leadership increases the probability of missteps in trial design, endpoint selection, or interactions with the FDA, which could delay or derail the ENABLE-2 initiation timeline despite current guidance for H2 2026.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password